Evidence map›Paper›PMID 40607419›Full record

ArticleFrontiers in immunology2025

The functional and clinical significance of nucleoporin NUP153 across human cancers: a systematic study based on multi-omics analysis and bench work validation.

Youfu He, Qing Wang, Zhaorui Wang, Menghui Duan, Yu Zhou, Jing Huang, Qiang Wu, Feichang Wu, Chen Li

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Youfu He *Medical College, Guizhou University, Guiyang, Guizhou, China.
Qing Wang *Department of Colorectal Surgery, the First People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Zhaorui WangTranslational Medicine Research Center, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan, China.
Menghui DuanDepartment of Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yu ZhouDepartment of Cardiology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Jing HuangDepartment of Cardiology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Qiang WuDepartment of Cardiology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Feichang WuDepartment of Oncology, Gaozhou People's Hospital, Maoming, Guangdong, China.
Chen LiDepartment of Pharmacy, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cancer is a group of highly heterogeneous malignant diseases, and early diagnosis plays a crucial role in improving patient outcomes. Nucleoporins, including Nucleoporin (NUP)153, are involved in key cellular processes such as nucleocytoplasmic transport and cell cycle regulation. However, the role of NUP153 in cancer, especially its expression patterns, mutations, diagnostic value, and relationship with the tumour immune microenvironment, remains insufficiently explored. Methods: This study analysed NUP153 expression data from public databases such as TCGA and GTEx. Expression differences between tumour and normal tissues were assessed using Wilcoxon signed-rank tests. Gene set enrichment analysis (GSEA) was used to identify the biological functions and pathways related to NUP153. The relationship between NUP153 expression and immune cell infiltration was evaluated using the TIMER database, while drug sensitivity data were obtained from the GDSC and CTRP databases. Additionally, NUP153 expression in gastric cancer tissues was validated using immunohistochemistry and RT-qPCR. Results: NUP153 showed significant expression variation across cancers, with high levels in cholangiocarcinoma, colorectal cancer, and head and neck squamous cell carcinoma. In gastric cancer, NUP153 was markedly upregulated compared to adjacent non-cancerous tissues. High NUP153 expression was linked to tumour-associated macrophage infiltration and correlated with poor prognosis in some cancers like Kidney Renal Papillary Cell Carcinoma and Sarcoma. Drug genomics analysis revealed that NUP153 expression predicted chemotherapy resistance, with imatinib and 4.5-dianilinophthalimide showing potential for inhibition in multiple cancers. Single-cell analysis and spatial transcriptomics further revealed that NUP153 expression drives proliferative states in mucus-producing cells in gastric cancer, and its expression was associated with immune cell infiltration patterns, particularly neutrophil and macrophage distribution in the tumour microenvironment. Conclusion: Our findings indicate that NUP153 is a critical factor in multiple cancers, especially gastric cancer, where its elevated expression holds promise as a diagnostic and prognostic biomarker. The results indicate that NUP153 plays a key role in modulating the immune microenvironment and driving tumour progression, positioning it as a potential target for future therapeutic interventions. However, additional studies are required to elucidate the specific molecular mechanisms underlying NUP153's function in cancer and to explore its clinical applicability.

Indexed as

Biomarkers, TumorNeoplasmsNuclear Pore Complex ProteinsClinical RelevanceGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMultiomicsPrognosisTumor MicroenvironmentBiomarkers, TumorNuclear Pore Complex Proteinschemotherapy sensitivitygastric cancerNUP153prognostic biomarkertumour immune microenvironment

Identifiers

PMID40607419
PMCPMC12213620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.